{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T18:51:00Z","timestamp":1776797460569,"version":"3.51.2"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,4,17]],"date-time":"2021-04-17T00:00:00Z","timestamp":1618617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,4,17]],"date-time":"2021-04-17T00:00:00Z","timestamp":1618617600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Mol Model"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1007\/s00894-021-04732-1","type":"journal-article","created":{"date-parts":[[2021,4,17]],"date-time":"2021-04-17T06:02:53Z","timestamp":1618639373000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Multi-conformation representation of Mpro identifies promising candidates for drug repurposing against COVID-19"],"prefix":"10.1007","volume":"27","author":[{"given":"Debarati","family":"Paul","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debadrita","family":"Basu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0692-8139","authenticated-orcid":false,"given":"Shubhra","family":"Ghosh Dastidar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,4,17]]},"reference":[{"key":"4732_CR1","unstructured":"Coronavirus Update (Live): 30,235,321 Cases and 948,335 Deaths from COVID-19 Virus Pandemic - Worldometer. https:\/\/www.worldometers.info\/coronavirus\/"},{"issue":"14","key":"4732_CR2","doi-asserted-by":"publisher","first-page":"3193","DOI":"10.3390\/molecules25143193","volume":"25","author":"B Strodel","year":"2020","unstructured":"Strodel B, Olubiyi O, Olagunju M et al (2020) High Throughput Virtual Screening to Discover Inhibitors of the Main Protease of the Coronavirus SARS-CoV-2. Molecules. 25(14):3193","journal-title":"Molecules."},{"key":"4732_CR3","doi-asserted-by":"crossref","unstructured":"Yang H, Bartlam M, Rao Z (2006) Drug design targeting the main protease, the Achilles heel of coronaviruses. Curr Pharm Des 12:4573\u20134590","DOI":"10.2174\/138161206779010369"},{"key":"4732_CR4","doi-asserted-by":"publisher","unstructured":"Anand K, Yang H, Bartlam M, Rao Z, Hilgenfeld R (2005) Coronavirus main proteinase: target for antiviral drug therapy. In: Schmidt A., Weber O., Wolff M.H. (eds) Coronaviruses with Special Emphasis on First Insights Concerning SARS. Birkh\u00e4user Advances in Infectious Diseases BAID. Birkh\u00e4user Basel. https:\/\/doi.org\/10.1007\/3-7643-7339-3_9","DOI":"10.1007\/3-7643-7339-3_9"},{"key":"4732_CR5","doi-asserted-by":"crossref","unstructured":"\u015awiderek K, Moliner V (2020) Revealing the molecular mechanisms of proteolysis of SARS-CoV-2 M pro by QM\/MM computational methods. Chem Sci 11:10626\u201310630","DOI":"10.1039\/D0SC02823A"},{"key":"4732_CR6","doi-asserted-by":"crossref","unstructured":"Chang G-G (2009) Quaternary structure of the SARS coronavirus main protease. Mol Biol SARS-Coronavirus:115\u2013128","DOI":"10.1007\/978-3-642-03683-5_8"},{"key":"4732_CR7","doi-asserted-by":"crossref","unstructured":"Hegyi A, Friebe A, Gorbalenya AE, Ziebuhr J (2002) Mutational analysis of the active centre of coronavirus 3C-like proteases. J Gen Virol 83:581\u2013593","DOI":"10.1099\/0022-1317-83-3-581"},{"key":"4732_CR8","doi-asserted-by":"crossref","unstructured":"Anand K (2002) Structure of coronavirus main proteinase reveals combination of a chymotrypsin fold with an extra alpha-helical domain. EMBO J 21:3213\u20133224","DOI":"10.1093\/emboj\/cdf327"},{"key":"4732_CR9","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41586-020-2223-y","volume":"582","author":"Z Jin","year":"2020","unstructured":"Jin Z, Du X, Xu Y et al (2020) Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors. Nature 582:289\u2013293","journal-title":"Nature"},{"key":"4732_CR10","doi-asserted-by":"crossref","unstructured":"Griffin JWD (2020) SARS-CoV and SARS-CoV-2 main protease residue interaction networks change when bound to inhibitor N3. J Struct Biol 211:107575","DOI":"10.1016\/j.jsb.2020.107575"},{"key":"4732_CR11","doi-asserted-by":"crossref","unstructured":"Xue X, Yu H, Yang H et al (2008) Structures of two coronavirus Main proteases: implications for substrate binding and antiviral drug design. J Virol 82:2515\u20132527","DOI":"10.1128\/JVI.02114-07"},{"key":"4732_CR12","doi-asserted-by":"publisher","unstructured":"Elmezayen AD, Al-Obaidi A, \u015eahin AT, Yelek\u00e7i K (2020) Drug repurposing for coronavirus (COVID-19): in silico screening of known drugs against coronavirus 3CL hydrolase and protease enzymes. J Biomol Struct Dyn. https:\/\/doi.org\/10.1080\/07391102.2020.1758791","DOI":"10.1080\/07391102.2020.1758791"},{"key":"4732_CR13","doi-asserted-by":"publisher","first-page":"fdd-2020-0010","DOI":"10.4155\/fdd-2020-0010","volume":"2","author":"SL Senanayake","year":"2020","unstructured":"Senanayake SL (2020) Drug repurposing strategies for COVID-19. Future Drug Discov 2:fdd-2020-0010. https:\/\/doi.org\/10.4155\/fdd-2020-0010","journal-title":"Future Drug Discov"},{"key":"4732_CR14","doi-asserted-by":"publisher","unstructured":"Koulgi S, Jani V, Uppuladinne M, Sonavane U, Nath AK, Darbari H, Joshi R (2020) Drug repurposing studies targeting SARS-CoV-2: an ensemble docking approach on drug target 3C-like protease (3CLpro). J Biomol Struct Dyn. https:\/\/doi.org\/10.1080\/07391102.2020.1792344","DOI":"10.1080\/07391102.2020.1792344"},{"key":"4732_CR15","doi-asserted-by":"crossref","unstructured":"Liu C, Zhou Q, Li Y et al (2020) Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases. ACS Cent Sci 6:315\u2013331","DOI":"10.1021\/acscentsci.0c00272"},{"key":"4732_CR16","doi-asserted-by":"crossref","unstructured":"Kupferschmidt K, CohenMar. 22 J, 2020, Pm 3:28 (2020) WHO launches global megatrial of the four most promising coronavirus treatments. In: Sci. AAAS. https:\/\/www.sciencemag.org\/news\/2020\/03\/who-launches-global-megatrial-four-most-promising-coronavirus-treatments","DOI":"10.1126\/science.abb8497"},{"key":"4732_CR17","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/s41586-020-2286-9","volume":"583","author":"DE Gordon","year":"2020","unstructured":"Gordon DE, Jang GM, Bouhaddou M et al (2020) A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature 583:459\u2013468","journal-title":"Nature"},{"key":"4732_CR18","doi-asserted-by":"crossref","unstructured":"Anand K, Ziebuhr J, Wadhwani P et al (2003) Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS. Drugs, Science 300:1763-7","DOI":"10.1126\/science.1085658"},{"key":"4732_CR19","doi-asserted-by":"publisher","first-page":"3277","DOI":"10.1021\/acs.jcim.0c00179","volume":"60","author":"J Wang","year":"2020","unstructured":"Wang J (2020) Fast identification of possible drug treatment of coronavirus disease-19 (COVID-19) through computational drug repurposing study. J Chem Inf Model 60:3277\u20133286","journal-title":"J Chem Inf Model"},{"key":"4732_CR20","doi-asserted-by":"crossref","unstructured":"Cava C, Bertoli G, Castiglioni I (2020) In silico discovery of candidate drugs against Covid-19. Viruses 12:404","DOI":"10.3390\/v12040404"},{"key":"4732_CR21","first-page":"166","volume":"7","author":"V Chandel","year":"2020","unstructured":"Chandel V, Raj S, Rathi B, Kumar D (2020) In silico identification of potent FDA approved drugs against coronavirus COVID-19 main protease: a drug repurposing approach. Chem Biol Lett 7:166\u2013175","journal-title":"Chem Biol Lett"},{"key":"4732_CR22","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.3390\/molecules26041100","volume":"26","author":"SA Cuesta","year":"2021","unstructured":"Cuesta SA, Mora JR, M\u00e1rquez EA (2021) In Silico Screening of the DrugBank Database to Search for Possible Drugs against SARS-CoV-2. Molecules 26:1100","journal-title":"Molecules"},{"key":"4732_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10930-020-09945-6","volume":"2","author":"MAA Ibrahim","year":"2021","unstructured":"Ibrahim MAA, Abdelrahman AHM, Allemailem KS et al (2021) In Silico Evaluation of Prospective Anti-COVID-19 Drug Candidates as Potential SARS-CoV-2 Main Protease Inhibitors. Protein J 2:1\u201314. https:\/\/doi.org\/10.1007\/s10930-020-09945-6","journal-title":"Protein J"},{"key":"4732_CR24","doi-asserted-by":"crossref","unstructured":"Madhusoodanan J (2020) News feature: to counter the pandemic, clinicians bank on repurposed drugs. Proc Natl Acad Sci 117:10616\u201310620","DOI":"10.1073\/pnas.2007346117"},{"key":"4732_CR25","doi-asserted-by":"crossref","unstructured":"Huynh T, Wang H, Luan B (2020) In silico exploration of the molecular mechanism of clinically oriented drugs for possibly inhibiting SARS-CoV-2\u2019s main protease. J Phys Chem Lett 11:4413\u20134420","DOI":"10.1021\/acs.jpclett.0c00994"},{"key":"4732_CR26","doi-asserted-by":"publisher","first-page":"12359","DOI":"10.1021\/acs.jmedchem.0c00606","volume":"63","author":"C Gil","year":"2020","unstructured":"Gil C, Ginex T, Maestro I et al (2020) COVID-19: drug targets and potential treatments. J Med Chem 63:12359\u201312386","journal-title":"J Med Chem"},{"key":"4732_CR27","doi-asserted-by":"publisher","unstructured":"Joshi RS, Jagdale SS, Bansode SB, et al (2020) Discovery of potential multi-target-directed ligands by targeting host-specific SARS-CoV-2 structurally conserved main protease. J Biomol Struct Dyn 1\u201316. https:\/\/doi.org\/10.1080\/07391102.2020.1760137","DOI":"10.1080\/07391102.2020.1760137"},{"key":"4732_CR28","doi-asserted-by":"crossref","unstructured":"Ullrich S, Nitsche C (2020) The SARS-CoV-2 main protease as drug target. Bioorg Med Chem Lett 30:127377","DOI":"10.1016\/j.bmcl.2020.127377"},{"key":"4732_CR29","doi-asserted-by":"crossref","unstructured":"Shaikh F, Zhao Y, Alvarez L et al (2019) Structure-based in silico screening identifies a potent ebolavirus inhibitor from a traditional Chinese medicine library. J Med Chem 62:2928\u20132937","DOI":"10.1021\/acs.jmedchem.8b01328"},{"key":"4732_CR30","doi-asserted-by":"crossref","unstructured":"Vora J, Patel S, Sinha S et al (2019) Structure based virtual screening, 3D-QSAR, molecular dynamics and ADMET studies for selection of natural inhibitors against structural and non-structural targets of chikungunya. J Biomol Struct Dyn 37:3150\u20133161","DOI":"10.1080\/07391102.2018.1509732"},{"key":"4732_CR31","doi-asserted-by":"crossref","unstructured":"Watanabe K, Ishikawa T, Otaki H et al (2017) Structure-based drug discovery for combating influenza virus by targeting the PA\u2013PB1 interaction. Sci Rep 7:9500","DOI":"10.1038\/s41598-017-10021-w"},{"key":"4732_CR32","doi-asserted-by":"crossref","unstructured":"Shechter S, Thomas DR, Lundberg L et al (2017) Novel inhibitors targeting venezuelan equine encephalitis virus capsid protein identified using in silico structure-based-drug-design. Sci Rep 7:17705","DOI":"10.1038\/s41598-017-17672-9"},{"key":"4732_CR33","doi-asserted-by":"crossref","unstructured":"Krishnan DA, Sangeetha G, Vajravijayan S et al (2020) Structure-based drug designing towards the identification of potential anti-viral for COVID-19 by targeting endoribonuclease NSP15. Inform Med Unlocked 20:100392","DOI":"10.1016\/j.imu.2020.100392"},{"key":"4732_CR34","doi-asserted-by":"crossref","unstructured":"Wishart DS, Knox C, Guo AC et al (2008) DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res 36:D901\u2013D906","DOI":"10.1093\/nar\/gkm958"},{"key":"4732_CR35","doi-asserted-by":"crossref","unstructured":"Huang J, MacKerell AD (2013) CHARMM36 all-atom additive protein force field: validation based on comparison to NMR data. J Comput Chem 34:2135\u20132145","DOI":"10.1002\/jcc.23354"},{"key":"4732_CR36","doi-asserted-by":"crossref","unstructured":"Jorgensen WL, Chandrasekhar J, Madura JD et al (1983) Comparison of simple potential functions for simulating liquid water. J Chem Phys 79:926\u2013935","DOI":"10.1063\/1.445869"},{"key":"4732_CR37","doi-asserted-by":"crossref","unstructured":"Phillips JC, Braun R, Wang W et al (2005) Scalable molecular dynamics with NAMD. J Comput Chem 26:1781\u20131802","DOI":"10.1002\/jcc.20289"},{"key":"4732_CR38","doi-asserted-by":"crossref","unstructured":"Darden T, Perera L, Li L, Pedersen L (1999) New tricks for modelers from the crystallography toolkit: the particle mesh Ewald algorithm and its use in nucleic acid simulations. Structure 7:R55\u2013R60","DOI":"10.1016\/S0969-2126(99)80033-1"},{"key":"4732_CR39","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1063\/1.447334","volume":"81","author":"S Nos\u00e9","year":"1984","unstructured":"Nos\u00e9 S (1984) A unified formulation of the constant temperature molecular dynamics methods. J Chem Phys 81:511\u2013519. https:\/\/doi.org\/10.1063\/1.447334","journal-title":"J Chem Phys"},{"key":"4732_CR40","doi-asserted-by":"crossref","unstructured":"Pettersen EF, Goddard TD, Huang CC et al (2004) UCSF chimera--a visualization system for exploratory research and analysis. J Comput Chem 25:1605\u20131612","DOI":"10.1002\/jcc.20084"},{"key":"4732_CR41","doi-asserted-by":"crossref","unstructured":"Friesner RA, Banks JL, Murphy RB et al (2004) Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem 47:1739\u20131749","DOI":"10.1021\/jm0306430"},{"key":"4732_CR42","doi-asserted-by":"crossref","unstructured":"Halgren TA, Murphy RB, Friesner RA et al (2004) Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J Med Chem 47:1750\u20131759","DOI":"10.1021\/jm030644s"},{"key":"4732_CR43","doi-asserted-by":"crossref","unstructured":"Friesner RA, Murphy RB, Repasky MP et al (2006) Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein\u2212ligand complexes. J Med Chem 49:6177\u20136196","DOI":"10.1021\/jm051256o"},{"key":"4732_CR44","doi-asserted-by":"crossref","unstructured":"Li J, Abel R, Zhu K et al (2011) The VSGB 2.0 model: a next generation energy model for high resolution protein structure modeling. Proteins Struct Funct Bioinform 79:2794\u20132812","DOI":"10.1002\/prot.23106"},{"key":"4732_CR45","doi-asserted-by":"crossref","unstructured":"Xue X, Yang H, Shen W et al (2007) Production of authentic SARS-CoV Mpro with enhanced activity: application as a novel tag-cleavage endopeptidase for protein overproduction. J Mol Biol 366:965\u2013975","DOI":"10.1016\/j.jmb.2006.11.073"},{"key":"4732_CR46","doi-asserted-by":"publisher","first-page":"ofaa241","DOI":"10.1093\/ofid\/ofaa241","volume":"7","author":"J Chen","year":"2020","unstructured":"Chen J, Xia L, Liu L et al (2020) Antiviral activity and safety of darunavir\/cobicistat for the treatment of COVID-19. Open Forum Infect Dis 7:ofaa241. https:\/\/doi.org\/10.1093\/ofid\/ofaa241","journal-title":"Open Forum Infect Dis"},{"key":"4732_CR47","doi-asserted-by":"crossref","unstructured":"Khalili JS, Zhu H, Mak NSA et al (2020) Novel coronavirus treatment with ribavirin: groundwork for an evaluation concerning COVID-19. J Med Virol 92:740-746","DOI":"10.1002\/jmv.25798"},{"key":"4732_CR48","doi-asserted-by":"publisher","first-page":"2526","DOI":"10.1021\/acsmedchemlett.0c00521","volume":"11","author":"Mohammad M Ghahremanpour","year":"2020","unstructured":"Ghahremanpour Mohammad M, Tirado-Rives Julian, Deshmukh Maya, Ippolito Joseph A, Zhang Chun-Hui, Cabeza Israel, de Vaca Maria-Elena, Liosi Karen S, Anderson, and William L. Jorgensen, (2020) Identification of 14 Known Drugs as Inhibitors of the Main Protease of SARS-CoV-2 ACS. Med Chem Lett 11:2526\u20132533","journal-title":"Med Chem Lett"},{"key":"4732_CR49","doi-asserted-by":"crossref","unstructured":"Tan ELC, Ooi EE, Lin C-Y et al (2004) Inhibition of SARS coronavirus infection in vitro with clinically approved antiviral drugs. Emerg Infect Dis 10:581\u2013586","DOI":"10.3201\/eid1004.030458"},{"key":"4732_CR50","doi-asserted-by":"publisher","first-page":"101646","DOI":"10.1016\/j.tmaid.2020.101646","volume":"35","author":"DC Hall","year":"2020","unstructured":"Hall DC, Ji H-F (2020) A search for medications to treat COVID-19 via in silico molecular docking models of the SARS-CoV-2 spike glycoprotein and 3CL protease. Travel Med Infect Dis 35:101646. https:\/\/doi.org\/10.1016\/j.tmaid.2020.101646","journal-title":"Travel Med Infect Dis"},{"key":"4732_CR51","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1007\/s00894-020-04600-4","volume":"26","author":"B Martiniano","year":"2020","unstructured":"Martiniano B, Alberto M-M, Irving B-R (2020) Identification of saquinavir as a potent inhibitor of dimeric SARS-CoV2 main protease through MM\/GBSA. J Mol Model 26:340","journal-title":"J Mol Model"},{"key":"4732_CR52","doi-asserted-by":"crossref","unstructured":"Colson P, Raoult D (2016) Fighting viruses with antibiotics: an overlooked path. Int J Antimicrob Agents 48:349\u2013352","DOI":"10.1016\/j.ijantimicag.2016.07.004"},{"key":"4732_CR53","doi-asserted-by":"crossref","unstructured":"Damle B, Vourvahis M, Wang E et al (2020) Clinical pharmacology perspectives on the antiviral activity of azithromycin and use in COVID-19. Clin Pharmacol Ther 108:201\u2013211","DOI":"10.1002\/cpt.1857"},{"key":"4732_CR54","doi-asserted-by":"crossref","unstructured":"Kaptein SJF, De Burghgraeve T, Froeyen M et al (2010) A derivate of the antibiotic doxorubicin is a selective inhibitor of dengue and yellow fever virus replication in vitro. Antimicrob Agents Chemother 54:5269\u20135280","DOI":"10.1128\/AAC.00686-10"},{"key":"4732_CR55","doi-asserted-by":"crossref","unstructured":"Imai H, Dansako H, Ueda Y et al (2018) Daunorubicin, a topoisomerase II poison, suppresses viral production of hepatitis B virus by inducing cGAS-dependent innate immune response. Biochem Biophys Res Commun 504:672\u2013678","DOI":"10.1016\/j.bbrc.2018.08.195"},{"key":"4732_CR56","doi-asserted-by":"crossref","unstructured":"Hou H-Y, Lu W-W, Wu K-Y et al (2016) Idarubicin is a broad-spectrum enterovirus replication inhibitor that selectively targets the virus internal ribosomal entry site. J Gen Virol 97:1122\u20131133","DOI":"10.1099\/jgv.0.000431"},{"key":"4732_CR57","doi-asserted-by":"crossref","unstructured":"Khan IH, Savarimuthu S, Leung MST, Harky A (2020) The need to manage the risk of thromboembolism in COVID-19 patients. J Vasc Surg 72:799\u2013804","DOI":"10.1016\/j.jvs.2020.05.015"},{"key":"4732_CR58","doi-asserted-by":"crossref","unstructured":"Cavalcanti DD, Raz E, Shapiro M et al (2020) Cerebral venous thrombosis associated with COVID-19. Am J Neuroradiol 41:1370\u20131376","DOI":"10.3174\/ajnr.A6644"},{"key":"4732_CR59","doi-asserted-by":"publisher","first-page":"118431","DOI":"10.1016\/j.lfs.2020.118431","volume":"260","author":"S Vinayagam","year":"2020","unstructured":"Vinayagam S, Sattu K (2020) SARS-CoV-2 and coagulation disorders in different organs. Life Sci 260:118431","journal-title":"Life Sci"},{"key":"4732_CR60","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.7326\/L20-1206","volume":"173","author":"D Wichmann","year":"2020","unstructured":"Wichmann D (2020) Autopsy Findings and Venous Thromboembolism in Patients With COVID-19. Ann Intern Med 173:1030","journal-title":"Ann Intern Med"},{"key":"4732_CR61","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/s41577-020-0354-x","volume":"20","author":"G Lemke","year":"2020","unstructured":"Lemke G, Silverman GJ (2020) Blood clots and TAM receptor signalling in COVID-19 pathogenesis. Nat Rev Immunol 20:395\u2013396","journal-title":"Nat Rev Immunol"},{"key":"4732_CR62","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s11239-020-02208-2","volume":"51","author":"A Goyal","year":"2021","unstructured":"Goyal A, Saigal S, Niwariya Y et al (2021) Successful use of tPA for thrombolysis in COVID related ARDS: a case series. J Thromb Thrombolysis 51:293\u2013296","journal-title":"J Thromb Thrombolysis"},{"key":"4732_CR63","doi-asserted-by":"crossref","unstructured":"Wang J, Hajizadeh N, Moore EE, et al (2020) Tissue plasminogen activator (tPA) treatment for COVID\u201019 associated acute respiratory distress syndrome (ARDS): A case series. J Thromb Haemost 18:1752\u20131755","DOI":"10.1111\/jth.14828"},{"key":"4732_CR64","unstructured":"Elissa Driggin, Mahesh Madhavan, Behnood Bikdeli, Sahil A. Parikh (2020) Prophylaxis and Treatment of Venous Thromboembolic Disease in COVID-19. In: Am. Coll. Cardiol.\u00a0https:\/\/www.acc.org\/latest-in-cardiology\/articles\/2020\/06\/12\/08\/16\/prophylaxis-and-treatment-of-venous-thromboembolic-disease-in-covid-19"},{"key":"4732_CR65","doi-asserted-by":"publisher","first-page":"2950","DOI":"10.1016\/j.jacc.2020.04.031","volume":"75","author":"B Bikdeli","year":"2020","unstructured":"Bikdeli B, Madhavan MV, Jimenez D et al (2020) COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up. J Am Coll Cardiol 75:2950\u20132973","journal-title":"J Am Coll Cardiol"},{"key":"4732_CR66","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1016\/j.chest.2020.05.559","volume":"158","author":"LK Moores","year":"2020","unstructured":"Moores LK, Tritschler T, Brosnahan S et al (2020) Prevention, Diagnosis, and Treatment of VTE in Patients With Coronavirus Disease 2019. Chest 158:1143\u20131163","journal-title":"Chest"},{"key":"4732_CR67","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1080\/14756366.2019.1690480","volume":"35","author":"S Jo","year":"2020","unstructured":"Jo S, Kim S, Shin DH, Kim MS (2020) Inhibition of SARS-CoV 3CL protease by flavonoids. J Enzyme Inhib Med Chem 35:145\u2013151","journal-title":"J Enzyme Inhib Med Chem"},{"key":"4732_CR68","doi-asserted-by":"crossref","unstructured":"Coppola M, Mondola R. (2020) Potential Unconventional Medicines for the Treatment of SARS-CoV-2. Drug Res (Stuttg) 70:286","DOI":"10.1055\/a-1170-4624"},{"key":"4732_CR69","doi-asserted-by":"crossref","unstructured":"Meneguzzo F, Ciriminna R, Zabini F, Pagliaro M (2020) Review of Evidence Available on Hesperidin-Rich Products as Potential Tools against COVID-19 and Hydrodynamic Cavitation-Based Extraction as a Method of Increasing Their Production. Processes 8:549. https:\/\/doi.org\/10.3390\/pr8050549","DOI":"10.3390\/pr8050549"},{"key":"4732_CR70","doi-asserted-by":"publisher","first-page":"109957","DOI":"10.1016\/j.mehy.2020.109957","volume":"144","author":"Yusuf A Haggag","year":"2020","unstructured":"Haggag Yusuf A et al (2020) Is Hesperidin Essential for Prophylaxis and Treatment of COVID-19 Infection? Med Hypotheses 144:109957","journal-title":"Med Hypotheses"},{"key":"4732_CR71","first-page":"1","volume":"8","author":"L Thakur","year":"2020","unstructured":"Thakur L, Vadhera P, Yadav N (2020) Combating Sars-Cov-19 By Phytochemicals: An In Silico Study. Innovare Journal of Life Sciences 8:1\u20134","journal-title":"Innovare Journal of Life Sciences"},{"key":"4732_CR72","doi-asserted-by":"crossref","unstructured":"Nasution Aini, Tambunan. (2017) Virtual screening of commercial cyclic peptides as NS2B-NS3 protease inhibitor of dengue virus serotype 2 through molecular docking simulation. IOP Conf Series: Materials Science and Engineering; 188: 012017","DOI":"10.1088\/1757-899X\/188\/1\/012017"},{"key":"4732_CR73","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1152\/physiolgenomics.00095.2020","volume":"52","author":"AS Imami","year":"2020","unstructured":"Imami AS, O\u2019Donovan SM, Creeden JF et al (2020) Oxytocin\u2019s anti-inflammatory and proimmune functions in COVID-19: a transcriptomic signature-based approach. Physiol Genomics 52:401\u2013407","journal-title":"Physiol Genomics"},{"key":"4732_CR74","doi-asserted-by":"crossref","unstructured":"Bonucci M, Raggi R, Vacca RA (2020) Polydatin and its potential protective effect on COVID-19. Clin Nutr 39:3850\u20133851","DOI":"10.1016\/j.clnu.2020.09.052"},{"key":"4732_CR75","doi-asserted-by":"publisher","DOI":"10.1111\/odi.13518","author":"L Lo Muzio","year":"2020","unstructured":"Lo Muzio L, Bizzoca ME, Ravagnan G (2020) New intriguing possibility for prevention of coronavirus pneumonitis: Natural purified polyphenols. Oral Dis. https:\/\/doi.org\/10.1111\/odi.13518","journal-title":"Oral Dis"}],"container-title":["Journal of Molecular Modeling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00894-021-04732-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00894-021-04732-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00894-021-04732-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,21]],"date-time":"2021-05-21T14:12:31Z","timestamp":1621606351000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00894-021-04732-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,17]]},"references-count":75,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["4732"],"URL":"https:\/\/doi.org\/10.1007\/s00894-021-04732-1","relation":{},"ISSN":["1610-2940","0948-5023"],"issn-type":[{"value":"1610-2940","type":"print"},{"value":"0948-5023","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,17]]},"assertion":[{"value":"19 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}],"article-number":"128"}}